Market research
CYP.AU Cynata Therapeutics Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.1
- Dividend yield
- Not available
- Beta
- 1.12
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000CYP7
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.1
- Dividend yield
- Not available
- Beta
- 1.12
About
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Research context
Cynata Therapeutics Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CYP.AU discussion.
5 years, 6 months ago
Cynata Therapeutics Limited is currently in a long term downtrend where the price is trading 23.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cynata Therapeutics Limited's total revenue sank by 8.5% to $33K since the same quarter in the previous year.
Its net income has dropped by 89.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 83.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Cynata Therapeutics Limited gets an overall score of 1/5.